Skip to main content
. 2025 May 22;16:1579483. doi: 10.3389/fimmu.2025.1579483

Table 2.

Response rate of group A and group B.

Response status RMA (group A, n=59) RMA+ Ibrutinib (group B, n=29) p Value
CR 10 (16.9) 12 (41.4) 0.013
PR 25 (42.4) 13 (44.8) 0.827
SD 14 (23.7) 2 (6.9) 0.054
PD 10 (16.9) 2 (6.9) 0.323
ORR 35 (59.3) 25 (86.2) 0.011

RMA, rituximab + methotrexate + cytarabine; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate.

Bold values: P < 0.05.